Page last updated: 2024-12-06

1,2-dipalmitoylphosphatidylglycerol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

## 1,2-Dipalmitoylphosphatidylglycerol (DPPG)

**1,2-Dipalmitoylphosphatidylglycerol (DPPG)** is a phospholipid, a type of lipid that forms the structural basis of cell membranes. It's specifically a **phosphatidylglycerol** molecule with two palmitic acid chains attached.

**Why is it important for research?**

DPPG plays a significant role in several areas of research, particularly in **membrane biology and biophysics**. Here's why:

* **Model Membrane Systems:** DPPG is a crucial component in creating **artificial membranes** or **liposomes**, which are used extensively in research to study various aspects of membrane function. These model membranes allow researchers to control the composition and environment, mimicking specific cellular conditions and investigating how lipids, proteins, and other molecules interact with the membrane.
* **Lung Surfactant:** DPPG is a major component of **lung surfactant**, a complex mixture of lipids and proteins that lines the alveoli in the lungs. This surfactant reduces surface tension and prevents the alveoli from collapsing during exhalation. Research on DPPG helps understand the mechanisms behind lung surfactant function and its role in lung diseases like respiratory distress syndrome.
* **Membrane Fusion:** DPPG plays a critical role in **membrane fusion**, a process essential for various cellular functions, including the release of neurotransmitters, cell division, and viral infection. Understanding DPPG's role in fusion can lead to new insights into these processes and potential therapeutic targets.
* **Drug Delivery:** DPPG is used in the development of **drug delivery systems** based on liposomes. It can help target specific cells and tissues, improving drug efficacy and reducing side effects.

**Other research applications:**

* **Investigating membrane fluidity and permeability.**
* **Studying the effects of various molecules (drugs, toxins, etc.) on membrane integrity and function.**
* **Developing new diagnostic and therapeutic tools.**

**In summary, 1,2-Dipalmitoylphosphatidylglycerol is an important research tool for understanding membrane structure and function, as well as for developing new technologies in medicine and biotechnology.**

dipalmitoyl phosphatidylglycerol : A phosphatidylglycerol in which the phosphatidyl acyl groups are both palmitoyl. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID65144
CHEMBL ID2286758
CHEBI ID60724
SCHEMBL ID13587396
MeSH IDM0096061

Synonyms (25)

Synonym
DB02043
[3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-hexadecanoyloxypropyl] hexadecanoate
4537-77-3
3-{[(2,3-dihydroxypropoxy)(hydroxy)phosphoryl]oxy}-2-(hexadecanoyloxy)propyl hexadecanoate
c16:0 phosphatidylglycerol
c16:0 pg
CHEBI:60724 ,
dipalmitoylphosphatidylglycerol
1,2-dipalmitoylphosphatidylglycerol
dipalmitoyl phosphatidylglycerol
hexadecanoic acid, 1-((((2,3-dihydroxypropoxy)hydroxyphosphinyl)oxy)methyl)-1,2-ethanediyl ester
unii-va9u6br3sb
va9u6br3sb ,
CHEMBL2286758
hexadecanoic acid, 1,1'-(1-((((2,3-dihydroxypropoxy)hydroxyphosphinyl)oxy)methyl)-1,2-ethanediyl)ester
dipalmitoylphosphatidylglycerol, dl-
SCHEMBL13587396
Q27888734
dl-dipalmitoylphosphatidylglycerol
BIABMEZBCHDPBV-UHFFFAOYSA-N
3-(((2,3-dihydroxypropoxy)(hydroxy)phosphoryl)oxy)propane-1,2-diyl dipalmitate
DTXSID70963375
STARBLD0008282
PD060150
pg 16:0_16:0

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Although it has been reported that the pharmacokinetics of drug-free Stealth liposomes is independent of dose within a certain range, clinical pharmacokinetic analysis of Doxil suggests a dose-dependent clearance saturation phenomenon when a broad dose range is examined."( Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models.
Bronstein, M; Gabizon, A; Horowitz, AT; Mak, L; Tzemach, D, 2002
)
0.31
" Seven additional patients were added at the 4th level (100 mg/m2) for further pharmacokinetic evaluation."( Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study.
Boulikas, T; Darli, E; Deliconstantinos, G; Rigatos, S; Stathopoulos, GP; Stathopoulos, JG; Viliotou, V; Vougiouka, M, 2005
)
0.33
" The pharmacokinetics following intramuscular injection of the multivesicular liposome of thymopentin labeled with fluorescein isothiocyanate in rats showed that the peak concentration of thymopentin was lower and elimination of it was slower significantly than that of thymopentin labeled with fluorescein isothiocyanate solution in the same dose."( [Preparation of sustained release multivesicular liposome for thymopentin and preliminary study on its pharmacokinetics in rats].
Jiao, YH; Mu, HJ; Sun, KX; Wang, T; Yao, DG; Yuan, ZZ, 2008
)
0.35

Bioavailability

ExcerptReferenceRelevance
" In conclusion, intranasal administration of chitosan coated liposome appeared to be effective to enhance the bioavailability as well as prolonged exposure of fexofenadine in rats."( Enhanced systemic exposure of fexofenadine via the intranasal administration of chitosan-coated liposome.
Han, HK; Lee, BJ; Qiang, F; Shin, HJ, 2012
)
0.38
" However, CBD-CS are preferred due to a better stability in water and improved bioavailability of siRNA on their surface."( siRNA carriers based on carbosilane dendrimers affect zeta potential and size of phospholipid vesicles.
Bryszewska, M; de la Mata, FJ; Garaiova, Z; Gomez-Ramirez, R; Hianik, T; Ionov, M; Klajnert, B; Pędziwiatr-Werbicka, E; Waczulikova, I; Wróbel, D, 2012
)
0.38
" A comparison of the pharmacokinetic parameters of the NI-LN suspensions with those of the NI solution prepared using only the surfactant polysorbate 80 revealed that although the AUC and bioavailability (59%) values were almost identical, a rapid absorption rate was still observed in the NI-LN suspensions."( Lipid nanoparticles with no surfactant improve oral absorption rate of poorly water-soluble drug.
Funakoshi, Y; Itai, S; Iwao, Y; Noguchi, S, 2013
)
0.39

Dosage Studied

ExcerptRelevanceReference
" Twenty-seven patients were included and 3-5 patients were selected for each dosage level; levels started at 25 mg/m2 and were increased by 25 to 125 mg/m2."( Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study.
Boulikas, T; Darli, E; Deliconstantinos, G; Rigatos, S; Stathopoulos, GP; Stathopoulos, JG; Viliotou, V; Vougiouka, M, 2005
)
0.33
" It was established that use of LS-Cyt contributes to a more rapid process of tissue regeneration and reduction of the inflammatory response in comparison with a non-liposomal dosage form."( Preparation and
Katsai, OG; Krasnopolskyi, YM; Ruban, OA, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
phosphatidylglycerolA glycerophosphoglycerol that is glycerol in which the hydrogen of one of the primary hydroxy groups has been replaced by a phosphatidyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (394)

TimeframeStudies, This Drug (%)All Drugs %
pre-199042 (10.66)18.7374
1990's86 (21.83)18.2507
2000's119 (30.20)29.6817
2010's130 (32.99)24.3611
2020's17 (4.31)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 8.75

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index8.75 (24.57)
Research Supply Index6.00 (2.92)
Research Growth Index4.75 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (8.75)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.25%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other399 (99.75%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]